VPRIV
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VPRIV (VPRIV).
VPRIV (velaglucerase alfa) is a recombinant form of human lysosomal glucocerebrosidase that hydrolyzes glucocerebroside to glucose and ceramide, replacing the deficient enzyme in Gaucher disease.
| Metabolism | Velaglucerase alfa is a protein; it is expected to be degraded into small peptides and amino acids via general protein catabolism pathways. |
| Excretion | Primarily metabolized via peptide hydrolysis; elimination is predominantly non-renal. Renal excretion accounts for <5% of the dose as intact drug. Fecal elimination of metabolites is negligible. |
| Half-life | Terminal elimination half-life is approximately 30 minutes (range 15-60 minutes) in Gaucher disease patients, necessitating intravenous infusion over 1-2 hours every other week. |
| Protein binding | Approximately 50% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Volume of distribution is approximately 0.5 L/kg, indicating distribution primarily within the extracellular space and limited tissue penetration. |
| Bioavailability | Not applicable; only available as an intravenous infusion. Bioavailability is 100% by the IV route. |
| Onset of Action | Intravenous: Clinical effects (e.g., reduction in splenomegaly, improvement in hematologic parameters) are typically observed within 3-6 months of initiating therapy. |
| Duration of Action | Duration of clinical effect extends over the dosing interval (2 weeks). After discontinuation, disease parameters may gradually return to pretreatment levels over months. |
60 U/kg intravenously every 2 weeks over 4 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No adjustment required for renal impairment as velaglucerase alfa is not renally eliminated. |
| Liver impairment | No adjustment required for hepatic impairment based on Child-Pugh score; safety not established in severe hepatic impairment. |
| Pediatric use | Same as adult: 60 U/kg intravenously every 2 weeks. Dosing is weight-based. |
| Geriatric use | No specific adjustment; use same weight-based dosing as adults. Monitor for tolerability. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VPRIV (VPRIV).
| Breastfeeding | No human data; velaglucerase alfa is a large protein (63 kDa) likely degraded in infant GI tract; M/P ratio unknown; caution advised. |
| Teratogenic Risk | No human data; animal studies (rats, rabbits) at 0.7-10x human exposure showed no teratogenicity but increased abortion in rabbits at 10x. Contains benzyl alcohol, which may cause 'gasping syndrome' in neonates if used near term. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["History of life-threatening hypersensitivity reaction to the active substance or any of the excipients."]
| Precautions | ["Hypersensitivity reactions including anaphylaxis have occurred.","Patients should be monitored for infusion-related reactions.","May cause the development of IgG antibodies to velaglucerase alfa.","Not studied in patients with moderate to severe hepatic impairment."] |
Loading safety data…
| Monitor liver function tests (ALT, AST), bilirubin, and iron deficiency; assess for infusion reactions (hypotension, chest pain); fetal ultrasound for growth if maternal Gaucher disease complications. |
| Fertility Effects | No human data; no effects on fertility observed in animal studies. |